US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

0.2660

-0.1300-32.83%

Post-market: 0.2611-0.0049-1.84%19:54 EDT

Volume:543.41K

Turnover:163.48K

Market Cap:4.42M

PE:-0.06

High:0.3900

Open:0.3700

Low:0.2605

Close:0.3960

Loading ...

Overview Company News Filings

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

Jail, caning for teen in SLE bike chase that killed LTA officer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Press Release: Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus Therapeutics Provides Business Updates and 2025 Overview

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

Press Release: Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Super League Enterprise files $100M mixed securities shelf

Super League Enterprise Inc Files for Mixed Shelf of up to $100 Mln – SEC Filing

THOMSON REUTERS

American Egg Board Debuts “Tower of Eggs” Activation in Roblox, Featuring Obstacle Gameplay and Recipe Challenges

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Super League Enterprise files to sell 3.03M shares of common stock for holders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":0.266,"timestamp":1743192000000,"preClose":0.396,"halted":0,"volume":543407,"hourTrading":{"tag":"盘后","latestPrice":0.2611,"preClose":0.266,"latestTime":"19:54 EDT","volume":22763,"amount":6039.5941,"timestamp":1743206064403},"delay":0,"floatShares":11261099,"shares":16604900,"eps":-4.481745,"marketStatus":"Market Closed","change":-0.13,"latestTime":"03-28 16:00:00 EDT","open":0.37,"high":0.39,"low":0.2605,"amount":163477.76307170998,"amplitude":0.32702,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.481745,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":0.396,"preHourTrading":{"tag":"盘前","latestPrice":0.3679,"preClose":0.396,"latestTime":"09:29 EDT","volume":37410,"amount":13575.103994699999,"timestamp":1743168560121},"postHourTrading":{"tag":"盘后","latestPrice":0.2611,"preClose":0.266,"latestTime":"19:54 EDT","volume":22763,"amount":6039.5941,"timestamp":1743206064403},"volumeRatio":3.0869329113584714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":11261099,"roa":"-54.85%","roe":"-244.57%","lyrEps":-13.672882,"volumeRatio":3.0869329113584714,"shares":16604900,"dividePrice":0,"high":0.39,"amplitude":0.32702,"preClose":0.396,"low":0.2605,"week52Low":0.2605,"pbRate":"1.26","psRate":"0.20","week52High":2.38,"institutionHeld":0,"latestPrice":0.266,"eps":-4.481745,"divideRate":0,"volume":543407,"delay":0,"ttmEps":-4.481745,"open":0.37,"prevYearClose":0.6175,"prevWeekClose":0.368,"prevMonthClose":0.381,"prevQuarterClose":0.6175,"fiveDayClose":0.368,"twentyDayClose":0.381,"sixtyDayClose":0.6312},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509407986","title":"Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407986","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509407986?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:05","pubTimestamp":1738757100,"startTime":"0","endTime":"0","summary":"- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021061/0/en/Zenas-BioPharma-Announces-Key-2024-Accomplishments-and-2025-Business-Objectives-to-Support-the-Global-Development-and-Commercialization-of-Therapies-for-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","ZBIO","BK4139"],"gpt_icon":0},{"id":"2509552283","title":"Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2509552283","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509552283?lang=en_us&edition=fundamental","pubTime":"2025-02-05 19:38","pubTimestamp":1738755480,"startTime":"0","endTime":"0","summary":"Exagen Inc.  shares soared 29.4% in the last trading session to close at $5.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.5% gain over the past four weeks.The recent surge in Exagen shares can be attributed to the ongoing positive trend that the company is witnessing post its announcement of a solid fourth quarter and full year 2024 preliminary results in January. XGN also received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus  and rheumatoid arthritis  biomarker assays. Also, XGN is witnessing a positive earnings estimate revision as loss estimate for 2025 improved from 70 cents to 58 cents in the past 30 days. As a result, investors are anticipating continued growth in earnings and revenue, which is expected to drive the stock’s upward momentum in the coming quarters.This company is expected to post quarterly loss of $0.27 per share in i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-exagen-xgn-29-113800709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RA","CAPR","SLE","BK4139","BK4077","XGN"],"gpt_icon":0},{"id":"2505312430","title":"Jail, caning for teen in SLE bike chase that killed LTA officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505312430","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505312430?lang=en_us&edition=fundamental","pubTime":"2025-01-23 11:37","pubTimestamp":1737603420,"startTime":"0","endTime":"0","summary":"The teen knew that he was wanted, and accelerated away from the late LTA officer Zdulfika Ahakasah to escape arrest.","market":"sg","thumbnail":"https://dam.mediacorp.sg/image/upload/s--bpHb1jwL--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/09/20/lta%20enforcement%20officer%20accident.jpg?itok=L-kkc82X","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--bpHb1jwL--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2024/09/20/lta%20enforcement%20officer%20accident.jpg?itok=L-kkc82X"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/jail-caning-teen-sle-bike-chase-killed-lta-officer-4891041","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2505145229","title":"RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published","url":"https://stock-news.laohu8.com/highlight/detail?id=2505145229","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505145229?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:00","pubTimestamp":1737460800,"startTime":"0","endTime":"0","summary":"Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or authorization. Additionally, new data describing the foundations for Talicia's recent FDA-approved label change to a more convenient three-times daily  \"breakfast, lunch, and dinner\" dosing routine, supporting patient adherence, has been published in the Journal of Clinical Pharmacology. The published data describe the use of physiologically-based pharmacokinetic  modeling and simulation to demonstrate pharmacokinetic equivalence of the TID regimen to the previous every 8-hour  dosing regimen. H. pylori infection affects approximately 35% of the U.S. adult population and is classified by the World Health Organization  as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer and a major risk factor for peptic ulcer disease. The result of a successful collaboration with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhills-talicia-adds-8-million-120000783.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhills-talicia-adds-8-million-120000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4124","RDHL","SLE","BK4161","BK4007","LU0053671581.USD","BK4144","BK4121","BK4568","BK4535","LU0054578231.USD","BK4585","BNTX","BK4588","BK4077","BK4548","ITT","SEER","BK4570","TEN","PPI","BK4139"],"gpt_icon":0},{"id":"2503630815","title":"Press Release: Autolus Therapeutics Provides Business Updates and 2025 Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2503630815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503630815?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769600,"startTime":"0","endTime":"0","summary":"- Ongoing commercial launch of AUCATZYL on track, with 24 treatment centers fully authorized as of January 10. - National Comprehensive Cancer Network adds AUCATZYL to its Clinical Practice Guidelines in Oncology . - Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23 R&D investor event. LONDON, Jan. 13, 2025  -- Autolus Therapeutics plc , a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces business updates and an overview of 2025 milestones.AUCATZYL was approved by the FDA on November 8, 2024. Autolus expects to complete authorization of the first 30 treatment centers, covering approximately 60% of the identified target patient population, by the end of January 2025. The Company expects to complete authorization of 60 treatment centers, covering approximately 90% of the target patient population, by the end of 2025.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4107","SLE","BK4006","LU2355687059.USD","CRS","BK4232","BK4022","R","ALL","BK4585","IE00B7SZL793.SGD","LU1699723380.USD","BK4588","IE00B66KJ199.SGD","IE00B19Z4B17.USD","LENZ","AUTL","LU2065731478.USD","CAR","BK4230","BK4077","BK4533","IE0031619046.USD","BK4139","LU0985320562.USD"],"gpt_icon":0},{"id":"2503084153","title":"Autolus Therapeutics Provides Business Updates and 2025 Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2503084153","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503084153?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769600,"startTime":"0","endTime":"0","summary":"- Ongoing commercial launch of AUCATZYL on track, with 24 treatment centers fully authorized as of January 10th. - National Comprehensive Cancer Network adds AUCATZYL to its Clinical Practice Guidelines in Oncology . - Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23rd R&D investor event. LONDON, Jan. 13, 2025  -- Autolus Therapeutics plc, a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces business updates and an overview of 2025 milestones.AUCATZYL was approved by the FDA on November 8, 2024. Autolus expects to complete authorization of the first 30 treatment centers, covering approximately 60% of the identified target patient population, by the end of January 2025. The Company expects to complete authorization of 60 treatment centers, covering approximately 90% of the target patient population, by the end of 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autolus-therapeutics-provides-business-updates-120000588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","BK4533","BK4006","IE00B7SZL793.SGD","BK4022","LU2355687059.USD","BK4139","BK4230","BK4585","LU1571399168.USD","ALL","LENZ","CRS","BK4588","IE0031619046.USD","LU0985320562.USD","BK4107","IE00B66KJ199.SGD","LU1699723380.USD","CAR","LU2065731478.USD","IE00B19Z4B17.USD","SLE","AUTL"],"gpt_icon":0},{"id":"2503004313","title":"Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503004313","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503004313?lang=en_us&edition=fundamental","pubTime":"2025-01-13 08:05","pubTimestamp":1736726700,"startTime":"0","endTime":"0","summary":"-- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 -- -- CB-010 ANTLER 2L LBCL and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008079/0/en/Caribou-Biosciences-Initiates-the-CB-010-GALLOP-Phase-1-Trial-in-Lupus-and-Provides-Outlook-for-Multiple-Clinical-Datasets-in-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","LU0868494617.USD","BK4022","BK4539","CAR","BK4211","LU0256863811.USD","LU0417517546.SGD","BK4195","BK4230","CRBU","BK4107","BK4585","BK4588","PFS","BK4139","SLE"],"gpt_icon":0},{"id":"2503393352","title":"Press Release: Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2503393352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503393352?lang=en_us&edition=fundamental","pubTime":"2025-01-13 01:00","pubTimestamp":1736701200,"startTime":"0","endTime":"0","summary":"Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results. New biomarkers on track for commercial launch in January 2025. Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn. CARLSBAD, Calif., Jan. 12, 2025  -- Exagen Inc. , a leading provider of autoimmune testing, today announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus  and rheumatoid arthritis  biomarker assays, with a planned commercial launch in January 2025.  The company also announced preliminary unaudited select financial results for the fourth quarter and full year ended December 31, 2024, in line with prior financial guidance.The company's new SLE and RA biomarkers will be incorporated into the AVISE CTD platform. Collectively, the company expect","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","IE00BGHQF748.EUR","BK4585","RA","LU1883839398.USD","LU1894683264.USD","BK4139","R","LU1894683348.USD","XGN","STT","BK4022","BK4588","IE00B3QW5Z07.USD","BK4232","IE00B64PRP62.GBP","BK4135","SLCT","BK4077","SLE","IE0034235188.USD"],"gpt_icon":0},{"id":"2502085244","title":"Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2502085244","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502085244?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:10","pubTimestamp":1736370600,"startTime":"0","endTime":"0","summary":"Adicet made significant progress in 2024 and is well-positioned for success in 2025: Advancing Phase 1 clinical trial evaluating ADI-001 across six autoimmune diseases; preliminary data in lupus nephritis  patients anticipated in 1H25, data from other patient cohorts expected in 2H25. Patient enrollment in systemic lupus erythematosus , systemic sclerosis , idiopathic inflammatory myopathy  and stiff person syndrome  expected to be initiated in 1Q25; initiation of patient enrollment in anti-neutrophil cytoplasmic autoantibody  associated vasculitis  expected in 2H25. REDWOOD CITY, Calif. & BOSTON, January 08, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2025.In September 2024, Adicet presented clinical biomarker data from the Phase 1 GLEAN trial of ADI-001 at the 9th Annual CAR-TCR Summit dem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-provides-corporate-highlights-211000326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","BK4230","IIM","BK4139","CAR","ACET","BK4022","SLE"],"gpt_icon":0},{"id":"2493768051","title":"GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2493768051","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493768051?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:00","pubTimestamp":1734962400,"startTime":"0","endTime":"0","summary":"– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec.  23, 2024  (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/23/3001257/0/en/GRI-Bio-Announces-European-Patent-Office-Issued-a-Decision-to-Grant-Notice-for-Patent-Covering-GRI-0803-and-Its-Library-of-500-Proprietary-Compounds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4007","BK4139","SLE","BK4077"],"gpt_icon":0},{"id":"2491110589","title":"Super League Enterprise files $100M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2491110589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491110589?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:40","pubTimestamp":1734126023,"startTime":"0","endTime":"0","summary":"16:35 EST Super League Enterprise (SLE) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-files-100m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-files-100m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2491854965","title":"Super League Enterprise Inc Files for Mixed Shelf of up to $100 Mln – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2491854965","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491854965?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:35","pubTimestamp":1734125721,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2490080343","title":"American Egg Board Debuts “Tower of Eggs” Activation in Roblox, Featuring Obstacle Gameplay and Recipe Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2490080343","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490080343?lang=en_us&edition=fundamental","pubTime":"2024-12-12 17:58","pubTimestamp":1733997480,"startTime":"0","endTime":"0","summary":"CHICAGO, Dec. 12, 2024  -- First-ever gaming activation from America’s egg farmers engages gamers through obstacle course gameplay, egg power-ups and in-game recipes.TheAmerican Egg Board announced today the launch of a first-of-its-kind, in-game activation exclusively in Roblox, an immersive gaming and creation platform: a “Tower of Eggs” pop-up filled with a dozen delicious egg recipes.Featured in popular Roblox obby  games now through February 5, 2025, it’s an uneggspected way for players to explore the unlimited potential of eggs to fuel their day—and gameplay!With a challenge to make recipes likeSausage, Egg and Cheese Roll-UpsandRamen Carbonara, players will run, jump and duck their way through a four-level tower obstacle course, each representing a real egg recipe comprised of ingredients and kitchen tools needed to complete the dish. As they run the course, players can unleash power-ups by breaking open eggs and cracking into their amazing possibilities. When they reach success","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oUHQQdnrwMwC63QrzDx_eA--~B/aD03MjA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fb961365d56cd2e5f1b41e432e4b399c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oUHQQdnrwMwC63QrzDx_eA--~B/aD03MjA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fb961365d56cd2e5f1b41e432e4b399c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/american-egg-board-debuts-tower-095800960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4565","BK4554","RBLX","BK4077","AFG","LU1861558580.USD","SLE","BK4535","BK4588","BK4085","BK4547","BK4585","LU1861559042.SGD","BK4107","BK4117","LU0348723411.USD","BK4551"],"gpt_icon":1},{"id":"2490884580","title":"Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2490884580","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490884580?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:01","pubTimestamp":1733778060,"startTime":"0","endTime":"0","summary":"All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2994080/24675/en/Fate-Therapeutics-Presents-New-Phase-1-Clinical-Data-of-FT819-Off-the-shelf-CAR-T-cell-Product-Candidate-for-Systemic-Lupus-Erythematosus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","BK4139","CAR","FATE","LU2463526074.USD","BK4109","BK4230","ASH","IE00B7SZL793.SGD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","SLE","BK4077","BK4022","CRS","BK4006"],"gpt_icon":0},{"id":"2490770882","title":"CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490770882","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490770882?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"-Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993974/0/en/CRISPR-Therapeutics-Presents-Data-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","LU1861558580.USD","BK4077","BK4022","LENZ","IE0031619046.USD","BK4109","IE00B66KJ199.SGD","CRSP","BK4585","LU2463526074.USD","BK4139","LU1861559042.SGD","BK4006","BK4556","BK4107","BK4230","BK4588","IE00B7SZL793.SGD","FL","ASH","AFG","IE00B19Z4B17.USD","BK4117","BK4094","CRS","SLE"],"gpt_icon":0},{"id":"2489285897","title":"Super League Enterprise files to sell 3.03M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2489285897","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489285897?lang=en_us&edition=fundamental","pubTime":"2024-12-06 19:21","pubTimestamp":1733484074,"startTime":"0","endTime":"0","summary":"06:17 EST Super League Enterprise (SLE) files to sell 3.03M shares of common stock for holders Published first on TheFly – the ultimate source for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-files-to-sell-3-03m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-files-to-sell-3-03m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLE","BK4077"],"gpt_icon":0}],"pageSize":16,"totalPage":9,"pageCount":3,"totalSize":131}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-3.47},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54},{"market":"US","date":"2024-08-14","symbol":"SLE","fiscalQuarterEnding":"2024/06","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.6},{"market":"US","date":"2024-05-15","symbol":"SLE","fiscalQuarterEnding":"2024/03","expectedEps":-1.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":1},{"market":"US","date":"2024-03-27","symbol":"SLE","fiscalQuarterEnding":"2023/12","expectedEps":-1.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711512000000,"reportTimeType":"post","actualEps":-3.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-03-28","current":-0.230354,"percent":0.696133,"low":-0.555206,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"high":-0.044016,"avg":-0.276106,"sd":0.108282,"marketCap":5671557},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557}],"updateTime":1743240930827}}}